Health care industry software and consulting provider Simulations Plus (NASDAQ: SLP) posted impressive results in the first quarter of its fiscal year 2021, continuing a trend that pushed this small-cap dynamo’s stock up 147% last year. Results, however, fell largely in line with analysts’ expectations, and investors engaged in a bit of profit-taking on Tuesday following Monday evening’s earnings release. Shares finished the Tuesday session 10% lower.
Simulations Plus provides modeling and simulation software used in drug discovery and research as well as for regulatory compliance in drug submissions. The company is also a leader in the application of machine learning to predict molecule properties in pharmaceutical chemistry. Let’s briefly review the organization’s latest earnings filing to see if it remains on track for further share price gains in the quarters ahead.